The predictive effect of the systemic immune-inflammation index for patients with small-cell lung cancer
Abstract
Aim: The purpose of this study was to investigate the predictive power of the systemic immune inflammation index (SII) based on neutrophil (N), platelet (P) and lymphocyte (L) on the clinical outcomes of patients with SCLC. Patients & methods: Blood samples of 228 patients were obtained 1 week before treatment to measure the SII (SII = P × N/L). Overall survival (OS) and progression-free survival (PFS) were estimated using the Kaplan–Meier curves and Cox regression models. Results: Higher SII was associated with poorer OS (p < 0.001) and poorer PFS (p < 0.001). Multivariable analyses further revealed SII as an independent prognostic factor for OS (p < 0.001) and PFS (p < 0.001). Conclusion: Pretreatment SII was a valuable prognostic factor for PFS and OS in SCLC patients.
Papers of special note have been highlighted as: • of interest; •• of considerable interest
References
- 1. . Cancer statistics, 2019. CA Cancer J. Clin. 69(1), 7–34 (2019).
- 2. Receipt of cancer treatment summaries and follow-up instructions among adult cancer survivors: results from a national survey. J. Cancer Survivorship 7(1), 32–43 (2013).
- 3. Non-small cell lung cancer, version 2.2013. J. Natl Compr. Cancer Netw. 11(6), 645–653 (2013).
- 4. Nomograms predict overall survival for patients with small-cell lung cancer incorporating pretreatment peripheral blood markers. J. Thorac. Oncol. 10(8), 1213–1220 (2015). •• Small-cell lung cancer is characterized by aggressive biology, rapid growth and early metastasis. The neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio incorporating hematological markers could more accurately predict individualized survival probability of small-cell lung cancer.
- 5. . Paradoxical roles of the immune system during cancer development. Nat. Rev. Cancer 6(1), 24–37 (2006).
- 6. . GITR ligand provided by thrombopoietic cells inhibits NK cell antitumor activity. J. Immunol. 189(1), 154–160 (2012).
- 7. . Direct signaling between platelets and cancer cells induces an epithelial–mesenchymal-like transition and promotes metastasis. Cancer Cell 20(5), 576–590 (2011).
- 8. . Platelet-derived nucleotides promote tumor-cell transendothelial migration and metastasis via P2Y2 receptor. Cancer Cell 24(1), 130–137 (2013).
- 9. Recruitment of monocytes/macrophages by tissue factor-mediated coagulation is essential for metastatic cell survival and premetastatic niche establishment in mice. Blood 119(13), 3164–3175 (2012).
- 10. Negative impact of neutrophil–lymphocyte ratio on outcome after liver transplantation for hepatocellular carcinoma. Ann. Surg. 250(1), 141–151 (2009).
- 11. Postoperative neutrophil-to-lymphocyte ratio change predicts survival of patients with small hepatocellular carcinoma undergoing radiofrequency ablation. PLoS ONE 8(3), e58184 (2013).
- 12. . Small cell lung cancer: recruitment of macrophages by circulating tumor cells. Oncoimmunology 5(3), e1093277 (2016).
- 13. . Tumor-associated macrophages and neutrophils in tumor microenvironment. Mediat. Inflamm. 2016, 6058147 (2016).
- 14. . Cancer-related inflammation. Nature 454(7203), 436–444 (2008).
- 15. Systemic immune-inflammation index predicts prognosis of patients after curative resection for hepatocellular carcinoma. Clin. Cancer Res. 20(23), 6212–6222 (2014).
- 16. Systemic inflammatory markers have independent prognostic value in patients with metastatic testicular germ cell tumours undergoing first-line chemotherapy. Br. J. Cancer 118(6), 825–830 (2018).
- 17. Systemic immune-inflammation index for predicting prognosis of colorectal cancer. World J. Gastroenterol. 23(34), 6261–6272 (2017).
- 18. Prognostic value of systemic immune-inflammation index in patients with gastric cancer. Chin. J. Cancer 36(1), 75 (2017).
- 19. Systemic immune-inflammation index predicts prognosis of patients with esophageal squamous cell carcinoma: a propensity score-matched analysis. Sci. Rep. 6, 39482 (2016).
- 20. Systemic immune-inflammation index predicts the combined clinical outcome after sequential therapy with abiraterone and docetaxel for metastatic castration-resistant prostate cancer patients. Prostate 78(4), 250–256 (2018).
- 21. Prognostic potential of neutrophil-to-lymphocyte ratio and lymphocyte nadir in stage III non-small-cell lung cancer. Future Oncol. 13(16), 1405–1414 (2017).
- 22. Prognostic value of systemic immune-inflammation index in patients with advanced non-small-cell lung cancer. Future Oncol. 14(25), 2643–2650 (2018). • Studies show that inflammatory processes can contribute to non-small-cell lung cancer progression and is associated with poor prognosis.
- 23. . Pretreatment neutrophil-to-lymphocyte ratio as a survival predictor for small-cell lung cancer. OncoTargets Ther. 9, 5761–5770 (2016).
- 24. . Prognostic role of the neutrophil–lymphocyte ratio in renal cell carcinoma: a meta-analysis. BMJ Open 5(4), e006404 (2015).
- 25. . Re: change in neutrophil-to-lymphocyte ratio in response to targeted therapy for metastatic renal cell carcinoma as a prognosticator and biomarker of efficacy. J. Urol. 196(6), 1634–1635 (2016).
- 26. . Systemic immune-inflammation index, based on platelet counts and neutrophil–lymphocyte ratio, is useful for predicting prognosis in small cell lung cancer. Tohoku J. Exp. Med. 236(4), 297–304 (2015).
- 27. . A novel systemic immune-inflammation index predicts survival and quality of life of patients after curative resection for esophageal squamous cell carcinoma. J. Cancer Res. Clin. Oncol. 143(10), 2077–2086 (2017).
- 28. Systemic immune-inflammation index predicts the clinical outcome in patients with nasopharyngeal carcinoma: a propensity score-matched analysis. Oncotarget 8(39), 66075–66086 (2017).
- 29. The systemic immune-inflammation index is an independent predictor of survival for metastatic colorectal cancer and its association with the lymphocytic response to the tumor. J. Translational Med. 16(1), 273 (2018).
- 30. . Prognostic value of systemic immune-inflammation index (SII) in cancers: a systematic review and meta-analysis. J. Lab. Precis. Med. 3, 29 (2018). •• Systemic immune-inflammation index has been shown to be predictive in many malignancies.
- 31. . On the cytokines produced by human neutrophils in tumors. Semin. Cancer Biol. 23(3), 159–170 (2013).
- 32. . Infections as a major preventable cause of human cancer. J. Intern. Med. 248(3), 171–183 (2000).
- 33. . Cancer related inflammation: the macrophage connection. Cancer Lett. 267(2), 204–215 (2008).
- 34. . Polymorphonuclear neutrophils and T lymphocytes: strange bedfellows or brothers in arms? Trends Immunol. 30(11), 522–530 (2009).
- 35. Platelets subvert T cell immunity against cancer via GARP-TGFβ axis. Sci. Immunol. 2(11), eaai7911 (2017).
- 36. . Platelets and granulocytes, in particular the neutrophils, form important compartments for circulating vascular endothelial growth factor. Angiogenesis 6(4), 283–287 (2003). • Liberation of VEGF from these compartments could well be of importance for tumor angiogenesis. Platelets and neutrophils could be important compartments for circulating VEGF.
- 37. . Dual roles for immunity in gastrointestinal cancers. J. Clin. Oncol. 28(26), 4045–4051 (2010).
- 38. . Hallmarks of cancer: the next generation. Cell 144(5), 646–674 (2011). • Inflammation runs through the development of tumor, and the role of inflammation in tumor has been paid more and more attention.
- 39. Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. J. Natl Cancer Inst. 106(6), dju124 (2014).
- 40. The systemic-immune-inflammation index independently predicts survival and recurrence in resectable pancreatic cancer and its prognostic value depends on bilirubin levels: a retrospective multicenter cohort study. Ann. Surg. 270(1), 139–146 (2019).